Abstract
Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Current Cancer Therapy Reviews
Title: Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Volume: 4 Issue: 2
Author(s): Amanda K. Miles, Alistair Roger, Richard Parkinson, Robert C. Rees and Stephanie E.B. McArdle
Affiliation:
Keywords: Prostate, peptides, immunotherapy, SEREX, T21
Abstract: Prostate cancer remains one of the most common cancers in men and treatment options for patients with advanced or metastatic disease are limited. Immunotherapeutic approaches, such as passive or active immunotherapy, have been shown to be successful in treating some cancer patients. These rely on the identification of cancer specific antigens that can be targeted by the immune system or used to diagnose as early as possible and/or to monitor the disease and its progression. Several prostate cancer antigens have already been identified; these include Prostate-Specific Membrane Antigen (PSMA), Prostate Specific Antigen (PSA), Prostatic Acid Phosphatase (PAP), PAGE-4, PSP 94, differential display 3, prostate androgen-regulated transcript 1 and six-transmembrane epithelial antigen prostate-restricted antigens and these represent potential candidate for immunotherapy against prostate cancer. The following review describes the importance of these antigens with a particular emphasis to the PAP antigen and T21, a recently identified prostate cancer associated antigen, as very promising targets for prostate therapy.
Export Options
About this article
Cite this article as:
Miles K. Amanda, Roger Alistair, Parkinson Richard, Rees C. Robert and McArdle E.B. Stephanie, Overview of Prostate Biomarkers as Potential Targets for Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310034
DOI https://dx.doi.org/10.2174/157339408784310034 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Biochemical Evaluation of a Series of Methanesulfonate Derivatives of 4-Hydroxyphenyl Ketone as Probes of the Active Site of Type 3 OF 17β-Hydroxysteroid Dehydrogenase Family of Enzymes
Letters in Drug Design & Discovery Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Vitamin D, Sunlight, and the Epidemiology of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Strategies for Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Analysis of Microarray Gene Expression Data
Current Bioinformatics Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Synthesis and Biological Potentials of 5-aryl-N-[4-(trifluoromethyl) phenyl]-1,3,4-oxadiazol-2-amines
Letters in Organic Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Harnessing Telomerase in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Prostate Cancer Prevention by Silibinin
Current Cancer Drug Targets Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews